cGxP.wire https://validator.w3.org/feed/docs/rss2.html Sagimet Reports 52-Week Denifanstat Acne Trial Results Agenus Wins First Global BOT+BAL Approvals in Armenia Teva Wins FDA Approval for Once-Monthly WELTRUZA Injection AviadoBio Reports Promising AVB-101 Biomarker Data in FTD Guardant Health Wins EU Approval for Breast Cancer Test Genentech Wins FDA Approval for Tecentriq in Stage III Colon Cancer Cullinan Therapeutics Doses First Patient in CLN-049 Phase 2 Newron Reviews FDA Clinical Hold on Evenamide Phase 3 Trial Lupin Wins FDA Approval for Phytonadione Injection Editas Medicine Clears EDIT-401 for First Human Trial Viatris to Acquire Pacira for $1.65 Billion Solu Therapeutics Begins STX-0712 Dosing in AML Cohort Lisata Therapeutics Secures New Certepetide Patent Innovent’s SYCUME Meets Phase 3 Goal in Inactive TED Life Biosciences Reports Initial ER-100 Phase 1 Data Pharvaris Reports Positive Phase 3 Deucrictibant Results Ultragenyx to Sell Rare Disease Voucher for $210 Million Roche Wins FDA Approval for Tecentriq in Stage III Colon Cancer Alpheus Medical Opens New Trial for Butterfly Glioblastoma Alumis Reports Durable Phase 3 Psoriasis Benefits With Envudeucitinib Verana Health and Bitfount Advance Eye Trial Screening Clarity Pharmaceuticals Completes SECuRE Trial Enrollment SOPHiA GENETICS and Myriad Advance Prostate Cancer Test Consano Bio to Highlight C-1101 for Sciatica at Conferences Vinci Pharmaceuticals Raises $8M to Advance EPIPLANT Platform Psilera Advances NIH-Funded Alcohol Use Disorder Research Alpha-9 Oncology to Present GRPR Imaging Data at EANM 2026 Bio-Techne Opens New Bristol GMP Facility for Cell Therapies Keenova to Present XIAFLEX and Men’s Health Data at SMSNA Edgewise Starts Phase 2 Trial of EDG-15400 for HFpEF Neurosterix Completes Phase 1 Studies of NTX-253 Lantern Pharma Advances LP-300 Phase 2 Trial in Taiwan Rocket Pharmaceuticals Advances RP-A501 Danon Disease Trial IQVIA Launches Explorer to Accelerate Commercial Decisions Ribo Files EU Clinical Trial Application for Obesity Drug RBD3133 Pearl Diagnostics Reports Clinical Evidence for MycoMEIA Assay Pfizer Wins FDA Approval for TUKYSA in Front-Line Breast Cancer Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial Glaukos Reports Three-Year Epioxa Results in Keratoconus argenx Reports Positive Phase 2 Results for FB102 in Celiac Disease IQVIA Launches AI Models to Predict Clinical Trial Outcomes Galderma Reports Three-Year Nemluvio Data in Atopic Dermatitis Bayer FDA Accepts Finerenone Application for CKD Without Diabetes argenx Discontinues Phase 3 UNITY Study in Sjögren’s Disease Theialife Aligns with FDA on ND10 Phase 3 Myopia Program Victory Square Announces U.S. Patent Allowance for Insu Atsena Reports Positive ATSN-201 Data in XLRS Trial Saol Therapeutics Completes Phase III Knee Pain Trial Enrollment Nuevocor Doses First Patient in NVC-001 Heart Disease Trial Boehringer Ingelheim Launches Quarterable PREVICOX Tablets